| Literature DB >> 24423780 |
Andrey V Cybulsky1, Michael Walsh2, Greg Knoll3, Michelle Hladunewich4, Joanne Bargman4, Heather Reich4, Atul Humar5, Susan Samuel6, Martin Bitzan7, Michael Zappitelli7, Allison Dart8, Cherry Mammen9, Maury Pinsk6, Norman Muirhead10.
Abstract
The KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for management of glomerulonephritis was recently released. The Canadian Society of Nephrology convened a working group to review the recommendations and comment on their relevancy and applicability to the Canadian context. A subgroup of adult nephrologists reviewed the guideline statements for management of glomerular disease in adults and agreed with most of the guideline statements developed by KDIGO. This commentary highlights areas for which there is lack of evidence and areas in need of translation of evidence into clinical practice. Areas of controversy or uncertainty, including the choice of second-line agents, are discussed in more detail. Existing practice variation also is addressed. The relevance of treatment recommendations to the Canadian practitioner is discussed.Entities:
Keywords: Canadian Society of Nephrology (CSN); Clinical practice guideline implementation; KDIGO (Kidney Disease: Improving Global Outcomes); glomerulonephritis; nephrotic syndrome
Mesh:
Year: 2014 PMID: 24423780 DOI: 10.1053/j.ajkd.2013.12.001
Source DB: PubMed Journal: Am J Kidney Dis ISSN: 0272-6386 Impact factor: 8.860